According to a recent survey, hereditary angioedema is a rare genetic disorder that affects approximately 1 in 50,000 people worldwide. It is characterized by recurrent episodes of swelling in the skin and mucous membranes, which can be painful and potentially life-threatening if they occur in the airways or digestive tract. The condition results from a deficiency or dysfunction of C1 inhibitor protein, which regulates immune system activity and prevents excess fluid from leaking out of blood vessels into surrounding tissues. Symptoms may first appear during childhood or adolescence and often worsen over time without proper treatment. There are currently several medications available to prevent attacks or treat acute symptoms, including plasma-derived C1 inhibitor replacement therapy, bradykinin receptor antagonists, and kallikrein inhibitors. However, many patients still struggle to obtain prompt diagnosis and access to these treatments due to limited awareness among healthcare providers and high costs associated with their use. Ongoing research efforts are focused on improving diagnostic accuracy, developing new therapies with longer duration of action or better tolerability profiles than existing options, and exploring potential links between hereditary angioedema and other inflammatory conditions such as autoimmune disease or cancer.
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation